English

Qlife postpones the publication of the year-end report for the financial year 2023 until 8 February 2024

Report this content

Qlife Holding AB has decided to postpone the publication of the year-end report for the financial year 2023. The previously announced date for publication was Monday, 5 February 2024. The new date for publication is Thursday, 8 February 2024.

The postponement is due to administrative reasons.

This information was submitted for publication, through the agency of the contact person set out above, on 04-02-2024 21:53 CET.

For more information please contact:

Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34

Qlife is a Swedish company based in Helsingborg, which develops and markets an innovative medical technology platform, Egoo.Health (”Egoo”), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company’s Certified Adviser. For additional information, please visit www.qlifeholding.com.

Subscribe